Pages that link to "Q33502338"
Jump to navigation
Jump to search
The following pages link to A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). (Q33502338):
Displaying 50 items.
- Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy (Q24187043) (← links)
- Colony-stimulating factors for prevention and treatment of infectious complications in patients with acute myelogenous leukemia (Q24202698) (← links)
- Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study (Q24670020) (← links)
- Timed sequential chemotherapy with concomitant granulocyte colony-stimulating factor for high-risk acute myelogenous leukemia: a single arm clinical trial (Q24792014) (← links)
- Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia (Q30497200) (← links)
- Economic analysis of filgrastim use for patients with acute myeloid leukaemia in the UK: a comparison of collection methods of resource use data (Q30711100) (← links)
- A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial (Q33350688) (← links)
- Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. (Q33380148) (← links)
- Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure (Q33384955) (← links)
- Clinical characteristics and treatment outcome of acute myeloid leukemia in elderly patients in Korea: a retrospective analysis (Q33875902) (← links)
- A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. (Q33939624) (← links)
- Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (Q33990856) (← links)
- Treatment options in Invasive Aspergillosis (Q34357504) (← links)
- Age and acute myeloid leukemia (Q34564663) (← links)
- Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients (Q34597777) (← links)
- XPD DNA nucleotide excision repair gene polymorphisms associated with DNA repair deficiency predict better treatment outcomes in secondary acute myeloid leukemia (Q34629500) (← links)
- Older adults with acute myeloid leukemia (Q34774180) (← links)
- The prognostic significance of IRF8 transcripts in adult patients with acute myeloid leukemia (Q34962889) (← links)
- Colony-stimulating factors for the management of neutropenia in cancer patients (Q35024453) (← links)
- The role of myelopoietic growth factors in managing cancer in the elderly (Q35024465) (← links)
- Filgrastim in patients with neutropenia: potential effects on quality of life (Q35024468) (← links)
- Mesenchymal stem cell therapy for acute radiation syndrome: innovative medical approaches in military medicine (Q35122122) (← links)
- Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making? (Q35128648) (← links)
- Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report (Q35215042) (← links)
- Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia (Q35462617) (← links)
- Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG (Q35525313) (← links)
- A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia (Q35628954) (← links)
- Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report (Q35687895) (← links)
- Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction (Q35848938) (← links)
- Effects of granulocyte-colony stimulating factor and the expression of its receptor on various malignant cells (Q36297673) (← links)
- Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia (Q36639295) (← links)
- Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia (Q36806921) (← links)
- Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature (Q36940606) (← links)
- Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience (Q37006786) (← links)
- Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia (Q37071108) (← links)
- Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course (Q37166414) (← links)
- Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin (Q37199950) (← links)
- A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia (Q37311249) (← links)
- Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: Practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation (Q37323006) (← links)
- What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? (Q37337422) (← links)
- Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia. (Q37438385) (← links)
- Comparison of survival outcomes among cancer patients treated in and out of clinical trials (Q37696455) (← links)
- Treatment of older patients with acute myeloid leukemia (AML): a Canadian consensus (Q38106983) (← links)
- Concise review: next-generation cell therapies to prevent infections in neutropenic patients (Q38193653) (← links)
- Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process (Q38542828) (← links)
- Intensive consolidation with G-CSF support: Tolerability, safety, reduced hospitalization, and efficacy in acute myeloid leukemia patients ≥60 years. (Q40138696) (← links)
- Infections in acute myeloid leukemia: an analysis of 382 febrile episodes (Q40376756) (← links)
- A multicenter randomized, double-blind, placebo-controlled late-phase II/III study of recombinant human interleukin 11 in acute myelogenous leukemia. (Q40458935) (← links)
- A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia (Q41872131) (← links)
- A systematic literature review of the efficacy, effectiveness, and safety of filgrastim (Q47938059) (← links)